MENU
+Compare
CNCR
ETF ticker:
AS OF
May 27 closing price
Price
$9.02
Change
+$0.14 (+1.58%)
Net Assets
6.95M

CNCR stock forecast, quote, news & analysis

CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CNCR with price predictions
Jun 27, 2025

Aroon Indicator for CNCR shows an upward move is likely

CNCR's Aroon Indicator triggered a bullish signal on June 27, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

Market Cap

The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.54B. The market cap for tickers in the group ranges from 7.18M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is APLM at 7.18M.

High and low price notable news

The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was 0%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was -28%. VOR experienced the highest price growth at 341%, while MRSN experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was 88%. For the same stocks of the ETF, the average monthly volume growth was 192% and the average quarterly volume growth was 252%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 80
Price Growth Rating: 57
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Unknown

Profile
Fundamentals
Details
Category
Health
Address
ETF Series Solutions615 East Michigan Street, Milwaukee, WisconsinEast Michigan
Phone
(414) 765-5586
Web
N/A